Stay updated on Sitravatinib Combo in Advanced NSCLC Clinical Trial

Sign up to get notified when there's something new on the Sitravatinib Combo in Advanced NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sitravatinib Combo in Advanced NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    0.7%
    Check dated 2025-07-11T03:12:54.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-04T00:25:32.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T16:49:20.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.2.
    Difference
    1%
    Check dated 2025-06-05T07:42:34.000Z thumbnail image
  6. Check
    75 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T14:24:57.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    The webpage has updated the reporting dates for study results and clarified the definitions of key endpoints such as Objective Response Rate (ORR), Overall Survival (OS), and Progression Free Survival (PFS). Additionally, the number of participants experiencing adverse events is now included in the study's safety analysis.
    Difference
    8%
    Check dated 2025-04-23T13:49:44.000Z thumbnail image

Stay in the know with updates to Sitravatinib Combo in Advanced NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo in Advanced NSCLC Clinical Trial page.